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Abstract
Both linezolid and cotrimoxazole are antibiotics that are well suited for oral therapy of bone and joint infections (BJI) caused by other-
wise resistant Gram-positive cocci (GPC) (resistance to ﬂuoroquinolones, maccolides, betalactamines). However, in this context, no
data are currently available regarding the safety and tolerance of these antibiotics in combination with rifampicin. The objective of this
study was to compare the efﬁcacy and safety of a combination of rifampicin and linezolid (RLC) with those of a combination of rifampi-
cin and cotrimoxazole (RCC) in the treatment of BJI. Between February 2002 and December 2006, 56 adult patients (RLC, n = 28;
RCC, n = 28), including 36 with infected orthopaedic devices (RLC, n = 18; RCC, n = 18) and 20 with chronic osteomyelitis (RLC,
n = 10; RCC, n = 10), were found to be eligible for inclusion in this study. Patients who discontinued antibiotic therapy within 4 weeks
of commencing treatment were considered to represent cases of treatment failure and were excluded. Rates of occurrence of adverse
effects were similar in the two groups, at 42.9% in the RLC group and 46.4% in the RCC group (p = 1.00), and led to treatment discon-
tinuation in four (14.3%) RLC and six (21.4%) RCC patients. Cure rates were found to be similar in the two groups (RLC, 89.3%, RCC,
78.6%; p = 0.47). Prolonged oral RLC and RCC therapy were found to be equally effective in treating patients with BJI caused by resis-
tant GPC, including patients with infected orthopaedic devices. However, the lower cost of cotrimoxazole compared with linezolid ren-
ders RCC an attractive treatment alternative to RLC. Further larger clinical studies are warranted to conﬁrm these preliminary results.
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Introduction
Prolonged therapy with a combination of antimicrobial agents
that reach bone concentrations higher than the minimal
inhibitory concentration for the pathogens concerned is usu-
ally recommended for the treatment of osteomyelitis [1]. In
the treatment of bone and joint infections (BJI) caused by
Gram-positive cocci (GPC), clinicians are confronted with
therapeutic problems arising from the resistance of patho-
gens, the lack of efﬁcacy of some antibiotics in bone infec-
tions and antibiotic toxicity during prolonged therapy.
Rifampicin has been shown to be effective in the treatment
of staphylococcal osteomyelitis, especially in patients with an
infected orthopaedic device, because of its capacity to eradi-
cate slow-growing bacteria that appear at the chronic phase
of osteomyelitis and bacteria adherent to prosthetic material
in infected joints [2–4]. However, although rifampicin exhib-
its anti-staphylococcal and anti-streptococcal activity, the
emergence of bacterial resistance when it is used alone is of
concern [5–7].
There are currently few or no published data on the efﬁ-
cacy and safety of the other available anti-GPC agents, which
include fusidic acid, cyclines, pristinamycin, lipopeptides and
quinupristin–dalfopristin for treating osteomyelitis [2,8–10].
Moreover, some antibiotics with anti-methicillin-resistant
Staphylococcus aureus (MRSA) activity, such as glycopeptides
and lipopeptides, are only available as a parenteral formula-
tion. Linezolid, the ﬁrst oxazolidinone agent, is an attractive
alternative in this setting [11–17]. However, there is concern
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regarding the emergence of linezolid-resistant strains [18–24]
and the bone marrow and neurological toxicity induced by
linezolid therapy [25–27]. In vitro studies have recently shown
that a combination of linezolid and rifampicin prevents the
emergence of rifampicin-resistant mutants [28].
Cotrimoxazole is another antimicrobial agent which has
been used for many years and which is active against some
Streptococcus spp. and most Staphylococcus spp., including
MRS [29,30]. Recent research has assessed the increasing
susceptibility of MRSA strains to cotrimoxazole [7,31–34],
which appears to offer an effective and economic alternative
for the treatment of MRS-related infections. However, few
studies have analysed the impact of this antibiotic in the
treatment of BJI [35,36].
The objective of the present retrospective study was to
compare the outcomes of prolonged therapy with a rifampi-
cin and linezolid combination (RLC) with those of a rifampi-
cin and cotrimoxazole combination (RCC), in terms of
efﬁcacy and safety, in the treatment of patients with chronic
osteomyelitis caused by GPC.
Materials and methods
Patients
A retrospective study was carried out examining the chart
records of patients with chronic osteomyelitis lasting
> 30 days. Patients included in this study had been treated
with either RLC or RCC for > 4 weeks in two separate hos-
pitals which work together as a referral centre in northern
France: the Dron Hospital, Tourcoing, and the Roger Salen-
gro Hospital, Lille. In these two centres, the choice of antibi-
otic regimens was based on protocols established 10 years
ago: microbiological samples were collected from patients
prior to administration of an empirical parenteral antibiotic
treatment for 5–7 days consisting of a glycopeptide-associ-
ated or not to a third-generation cephalosporin.
In light of the microbiological results, patients with GPC
infections were subsequently given our standard treatment
of a combination of rifampicin and levoﬂoxacin unless they
were known to be intolerant to ﬂuoroquinolones, were
infected by ﬂuoroquinolone-resistant GPC strains or had a
mixed infection of GPC and Gram-negative strains. This sec-
ond group, which constitutes the subjects of this paper, were
treated either with RLC (28 patients treated during the per-
iod February 2002 to December 2004) or with RCC (28
patients treated during January 2005 to December 2006).
This change of drug regime represented a response to
increasing reports of linezolid-induced toxicity. The RLC
patients were also part of a cohort of 66 patients included
in a previous study investigating the efﬁcacy of prolonged
linezolid treatment in chronic osteomyelitis [25].
The drug regime was as follows. Patients in the RLC
group were given linezolid (600 mg twice daily) and rifampi-
cin (10 mg/kg twice daily, maximum 900 mg twice daily),
administered i.v. for the ﬁrst week and subsequently orally,
and were subject to weekly haematological monitoring.
Patients in the RCC group were given cotrimoxazole (sulfa-
methoxazole 40 mg/kg/day, trimethoprim 8 mg/kg/day) and
rifampicin (10 mg/kg/12 h, maximum 900 mg/12 h) according
to the same protocol, except for three patients who refused
to be hospitalized and whose treatment was initiated orally.
There were no changes in surgical protocols during the
two treatment periods. Patients with chronic prosthetic joint
infection underwent revision of the implants with one- or
two-stage exchange with the use of a spacer according to
the extent of infection, determined perioperatively. Implant
retention or permanent removal of the implant was decided
in cases of poor clinical condition, contraindicating any inva-
sive surgery or further re-implantation. In cases of osteosyn-
thesis infection, prosthetic material was removed unless the
patient was inoperable. Patients were followed up for
‡ 12 months after the end of treatment (EOT).
Only patients with documented bacteriological osteomyeli-
tis based on intraoperative samples and/or joint aspiration cul-
tures were enrolled in the study. Osteomyelitis was diagnosed
according to the presence of: fever > 38 C; inﬂammation or
purulent discharge in the area of osteosynthesis devices; bio-
logical inﬂammatory syndrome (erythrocyte sedimentation
rate > 50 mm/h and C-reactive protein > 10 mg/L); radiologi-
cal evidence of loose osteosynthesis devices or prostheses
(luxation or pseudoarthrosis); evidence of bone infection on
plain radiography; leukocytes on direct examination of intraop-
erative samples, and/or positive Gram-stained smear.
The following demographic parameters were analysed:
age; sex; diabetes mellitus status; type of osteomyelitis; pres-
ence of an infected orthopaedic device; presence of a ﬁstula,
and type of surgical intervention.
Patients gave their consent for chart review performed
during follow-up consultations. No ethical approval for chart
review studies is currently required by our local institutional
ethical review board.
Outcome
In patients with an orthopaedic device, remission of infection
was deﬁned by a functional pain-free implant associated with
C-reactive protein values of < 10 mg/L and an absence of
radiological signs of either loosening or pseudoarthrosis. In
patients with chronic osteomyelitis, remission of infection
was deﬁned by the absence of local signs of infection, puru-
1164 Clinical Microbiology and Infection, Volume 15 Number 12, December 2009 CMI
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 15, 1163–1169
lent discharge or radiological signs of active osteomyelitis
(e.g. bone destruction, new intramedullar or skin and soft-
tissue abscesses, fracture) and C-reactive protein values of
< 10 mg/L. In both cases these factors were determined
after a post-treatment period of ‡ 12 months. Failure was
deﬁned by any other outcome, lack of data on follow-up or
early discontinuation of antibiotic regimen (< 4 weeks)
because of toxicity.
Follow-up
Biological tolerance to therapy was evaluated focusing specif-
ically on haematological, hepatic and renal parameters during
treatment. Anaemia was deﬁned as a haemoglobin value of
< 9.0 g/dL, leukopenia as total leukocyte count of < 4 · 109/
L, and thrombocytopenia as a platelet count of < 100 · 109/
L. Clinical tolerance of therapy was evaluated based on neu-
rological signs, skin allergy and gastrointestinal disturbances.
Patient clinical and biological parameters were followed
for 4 weeks after discharge from hospital, then at the EOT,
and at 6 and 12 months thereafter. Further contacts were
made via consultations or telephone. Because linezolid is not
approved in France for the treatment of osteomyelitis and
cannot be prescribed for > 28 consecutive days, each patient
gave consent after information about the potential toxicity of
linezolid had been provided by a senior physician.
Statistical analysis
Comparisons between the RLC and RCC groups were made
using Fisher’s exact test for categorical values and Student’s
t-test for mean values; the signiﬁcance level was set at
p < 0.05. A Kaplan–Meier analysis with log-rank test was
performed to compare relapse-free survival rates at 2 years
between the RLC and RCC groups.
Results
Clinical characteristics
All patients had chronic infections of > 30 days duration and
all infections involving prosthetic material had occurred
> 2 months after surgical intervention. Two patients who
received RCC were considered as failures and rejected from
the study: one patient had to discontinue RCC treatment
after 6 days because of a skin rash and the other died of
co-morbidities during antibiotic therapy.
The clinical characteristics of the two groups were similar
and are detailed in Table 1. Median hospital stay was 15 days
(mean 18.0 ± 9.8 days, range 6–42 days) in the RLC group
and 14 days (mean 15.4 ± 10.05 days, range 0–43 days) in
the RCC group. Mean duration of therapy was 17.8 ±
7.5 weeks (range 8–36 weeks) in the RLC group and
15.4 ± 10.1 weeks (range 1–53 weeks) in the RCC group
(Table 2). In both the RLC and RCC treatment groups, dura-
tions of treatment were similar in patients with prosthetic
infections and patients with osteomyelitis.
Microbiological characteristics
The most frequent pathogens were found to be methicillin-
resistant staphylococci, which represented 20 of 32 (62.5%)
pathogens in the RLC group and 19 of 45 (42.2%) in the
RCC group. Methicillin-susceptible staphylococci were less
frequent and represented four of 32 (12.5%) pathogens in
TABLE 1. Comparison of patients with chronic osteo-
myelitis treated with rifampicin–linezolid combination (RLC)
or rifampicin–cotrimoxazole combination (RCC)
Characteristics
RLC patients
(n = 28)
RCC patients
(n = 28) p-value
Mean age, years (range) 57 (22–83) 60 (22–83) 1.00
Sex, male/female 15/13 16/12 1.00
Prosthetic joints, n (%) 11 (39.3) 11 (39.3) 1.00
One-stage exchange 3 (10.7) 0 0.24
Two-stage exchange 3 (10.7) 5 (17.9) 0.70
Debridement with retention 4 (14.3) 6 (21.4) 0.73
Permanent removal 1 (3.6) 0 1.00
Osteosynthesis, n (%) 6 (21.4) 7 (25.0) 1.00
Removal before antibiotherapy 6 (21.4) 5 (17.9) 1.00
Removal during antibiotherapy 0 0 1.00
No removal 0 2 (7.2) 0.49
No prosthetic material, n (%) 11 (39.3) 10 (35.7) 1.00
Long bone osteomyelitis 5 (17.9) 6 (21.4) 1.00
Diabetic foot osteomyelitis 4 (14.3) 2 (7.1) 0.67
Spondylodiscitis 2 (7.1) 0 0.49
Sternitis 0 2 (7.1) 0.49
Fistula, n (%) 10 (35.7) 9 (32.1) 1.00
Risk factors, n (%)
Malignancy 0 3 (10.7) 0.24
Steroid therapy 1 (3.6) 1 (3.6) 1.00
Diabetes mellitus 8 (28.6) 6 (21.4) 0.76
Chronic renal failure 1 (3.6) 1 (3.6) 1.00
TABLE 2. Duration of treatment (weeks, mean ±
standard deviation) according to antibiotic regimen
(rifampicin–cotrimoxazole, RCC, vs. rifampicin–linezolid
combination, RLC), presence of a devicea and surgical
management
RLC
patients
RCC
patients p-value
Mean
duration
No Mean
duration
No Mean
duration
No device 16.4 ± 7.9 11 15.0 ± 8.8 10 0.5971
Removed/exchanged
device
18.1 ± 8.0 13 18.3 ± 16.0 10 0.5765
One-stage exchange 20.7 ± 5.8 3 – 0 –
Two-stage exchange 14.7 ± 8.3 3 14.6 ± 13.8 5 0.7857
Permanent removal 18.4 ± 9.2 7 22.0 ± 18.6 5 0.8763
Retained device 20.2 ± 10.7 4 13.2 ± 4.6 8 0.1091
Total patients in group 17.8 ± 7.5 28 15.4 ± 10.1 28
aProsthesis or osteosynthesis.
No: number of patients
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the RLC group and 10 of 45 (22.2%) in the RCC group. This
is detailed in Table 3. Neither community-acquired MRSA
nor vancomycin-resistant Enterococcus spp. were detected. In
both the RLC and RCC groups, all strains were susceptible
to rifampicin, as well as to linezolid and cotrimoxazole,
respectively. No case of acquired bacterial resistance to the
antibiotic treatment was observed.
Mixed infections (GPC associated with Gram-negative
bacilli or anaerobes) were noted in one patient (3.1% of
pathogens) in the RLC group and in seven patients (21.7%)
in the RCC group.
Clinical outcome
Cure rates were similar in the RLC and RCC groups (89.3%
and 78.6%, respectively; p = 0.47). Table 4 summarizes cure
rates according to the antibiotic regimen, the presence of a
device (osteosynthesis or prosthesis) and mode of surgical
management.
In the case of prosthetic joint infections, all patients would
normally have had undergone one- or two-stage exchange,
but in 12 patients (eight in the RCC group, four in the RLC
group) co-morbidity or severe joint damage was too great
to support invasive surgery and thus it was decided to retain
the implant in these patients. The 2-year follow-up time-
point was achieved for 26 patients in the RCC group (two
patients were lost from follow-up) and 25 patients in the
RLC group (two patients were lost from follow-up and a
third was cured but died because of co-morbidities
18 months after the EOT).
At the 2-year follow-up point, treatment was considered
to have been successful in 20 of 26 patients (76.9%) in the
RCC group, and in 21 of 25 patients (84.0%) in the RLC
group (p = 0.7265). There was no difference in outcome
according to the microorganism isolated, the presence of
infected prosthetic material, or the type of surgical manage-
ment (retained vs. removed device, or, in cases of device
removal, one-stage vs. two-stage exchange or permanent
removal). Relapse-free survival at 2 years after EOT was sim-
ilar for the RLC and RCC groups (p = 0.1831) (Fig. 1).
Adverse events
The occurrence of adverse effects was similar in the two
groups: 42.9% of RLC-treated patients and 46.4% of RCC-
treated patients showed adverse reactions (Table 5). In the
RLC group, median time from drug initiation and anaemia
onset was 9 weeks (range 8–14 weeks), by contrast with the
RCC group, in which no patients suffered from anaemia.
Reversible peripheral neuropathy was recorded in one
(3.6%) patient, who had to interrupt the RLC regimen after
36 weeks of treatment. In the RCC group, skin rash, ele-
vated hepatic enzymes and gastrointestinal disturbance were
reported in three, three and seven patients, respectively,
TABLE 3. Distribution of pathogens isolated from patients
treated with the rifampicin–linezolid combination (RLC) or
the rifampicin–cotrimoxazole combination (RCC)
Pathogens
RLC group,
n (% of total
number of strains)
RCC group,
n (% of total
number of strains)
MRSA 11 (34.4) 10 (22.2)
MSSA 4 (12.5) 7 (15.6)
MRCNS 9 (28.1) 9 (20.0)
MSCNS 0 (0) 3 (6.7)
Enterococcus spp. 5 (15.6) 0 (0)
Streptococcus spp. 2 (6.2) 5 (11.1)
Other 1 (3.1) 11 (24.4)
Total 32 45
MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible
Staphylococcus aureus; MRCNS, methicillin-resistant coagulase-negative
staphylococci; MSCNS, methicillin-susceptible coagulase-negative staphylococci.
TABLE 4. Comparison of cure rates (no. of patients cured/
no. of patients treated), according to antibiotic regimen
(rifampicin–cotrimoxazole combination, RCC, vs. rifampicin–
linezolid combination, RLC), presence of a devicea and
surgical management
RLC
patients, n (%)
(n = 28)
RCC
patients, n (%)
(n = 28) p-value
No device 9/11 (82) 9/10 (90) 1.00
Removed/exchanged device 12/13 (92) 7/10 (70) 0.28
One-stage exchange 2/3 (67) 0 –
Two-stage exchange 3/3 (100) 4/5b (80) 1.00
Permanent removal 7/7 (100) 3/5 (60) 0.15
Retained device 4/4 (100) 6/8c (75) 0.52
aProsthesis or osteosynthesis.
bOne failure concerned a patient who had to interrupt RCC 6 days after
initiation for skin rash.
cOne failure concerned a patient who died because of co-morbidities during
antibiotherapy.
FIG. 1. Relapse-free survival at 2 years after end-of-treatment in the
rifampicin–linezolid combination (RLC) and rifampicin–cotrimoxazole
combination (RCC) groups.
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with mean times from drug initiation to onset of the adverse
effect of 3.2 (range 1–6), 3.3 (range 1–6) and 4.6 (range 0.3–
12) weeks, respectively. Equivalent effects were experienced
by no, two and four patients, respectively, in the RLC-
treated group.
Discussion
The aim of the present retrospective study was to compare
the efﬁcacy and safety of prolonged RLC and RCC therapy
in patients with GPC bone and joint infections. The success
rates were similar in the two groups, at 89.3% and 78.6% in
the RLC and RCC groups, respectively (p = 0.47). The suc-
cess rate in the RLC group is comparable with rates in previ-
ous clinical studies in which linezolid was administered alone
[14–17].
The success rate in our RCC group was higher than that
reported by Stein et al. [35], who analysed the impact of
cotrimoxazole as monotherapy in the treatment of infected
orthopaedic implants and found an overall success rate of
66.7%. The higher success rate in our analysis may be
explained by the positive impact of rifampicin administered in
addition to cotrimoxazole, or possibly by better consistency
between antibiotherapy and microbiology in our study:
indeed 56% of the Staphylococcus species in the study by
Stein et al. [35] were isolated from ﬁstulae, which may not
reﬂect the microbiology of the infected bone sites. Three
failures in Stein et al. [35] were related to the isolation of
cotrimoxazole-resistant Staphylococcus spp. strains, but no
detailed data about risk factors were given. In our study,
there was no selection of resistance to antibiotic treatment
within the initial bacterial population during RCC, but new
cotrimaxozole-resistant bacterial species were isolated
8–38 weeks after completion of this regimen in three
patients who had clinical failure. These patients, however,
had risk factors for relapsing infections, namely, the presence
of sequestra, retention of an infected orthopaedic device,
and concurrent urinary tract infection, which were probably
responsible for the re-infection. The clinical success rate in
our study was lower than that reported in the study by San-
chez et al. [36], in which 20 of 21 (95.2%) patients treated
with RCC for staphylococcal osteoarticular infections were
cured. However, the true impact of the RCC regimen was
difﬁcult to assess in this study because, prior to RCC treat-
ment, the patients had received prolonged parenteral therapy
with other antimicrobials for a mean duration of 18 days
(range 2–40 days) [36].
In the present study, rates of adverse events were similar
in the RLC and RCC groups. In the RLC group, 12 patients
(42.9%) had drug-related adverse effects. These results dif-
fered signiﬁcantly from those established in previous studies,
especially regarding the frequency of anaemia episodes, which
was < 5% in previous studies [14–17,37]. This higher rate of
anaemia observed in this study may be explained by longer
treatment duration and a greater mean patient age [38]. It is
of note that no episode of thrombocytopenia was observed
in the RLC group, in contradiction to some previous studies
[14–16,37]. Our results are nevertheless consistent with
those of Soriano et al. [39], suggesting a protective effect of
rifampicin on linezolid-induced thrombocytopenia.
Prolonged peripheral neuropathy occurred in one of the
28 RLC patients, despite pyridoxine supplementation. This
serious adverse event related to linezolid has been reported
earlier, but no data on risk factors are currently available
[26,27]. Clinicians should be aware of this when prescribing
linezolid and should warn patients to stop linezolid promptly
if abnormal effects occur.
In the RCC group, 13 patients (46.4%) experienced
adverse effects, reﬂecting a higher rate than that reported in
TABLE 5. Adverse events reported in
patients treated with the rifampicin–
linezolid combination (RLC) or the
rifampicin–cotrimoxazole
combination (RCC)
RLC (n = 28) RCC (n = 28)
p-value
Patients,
n (%)
Discontinuations,
n (%)
Patients,
n (%)
Discontinuations,
n (%)
Reversible anaemia 4 (14.3)a 3 (10.7) 0 0 0.05
Leukopenia 0 0 2 (7.7) 0 0.49
Thrombocytopenia 0 0 0 0 –
Peripheral neuropathy 1 (3.6) 1 (3.6) 0 0 1.00
Headache 2 (7.2) 0 0 0 0.49
Elevated hepatic enzymes 2 (7.2) 0 3 (10.7) 1 (3.6) 1.00
Gastrointestinal disturbance 4 (14.3) 0 7 (25.0) 3 (11.5) 0.50
Renal failure 0 0 0 0 –
Skin rash or pruritus 0 0 3 (10.7) 3 (10.7) 0.23
Total 12b (42.9) 4 (14.3) 13c (46.4) 6c (21.4) 1.00
aAll patients required blood transfusion.
bOne patient experienced headache and elevated hepatic enzyme levels.
cTwo patients experienced elevated hepatic enzyme levels in association with another adverse event (skin rash
leading to drug discontinuation, or neutropenia).
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the study of Sanchez et al. [36]. This discrepancy may be
explained by the longer treatment duration in our study
(15.4 vs. 4.9 weeks). Skin allergy and gastrointestinal side-
effects led to RCC discontinuation in six patients. However,
close monitoring of these patients enabled rapid recovery
with no sequelae.
The present study had several limitations. Firstly, its popu-
lation was small as a result of narrow inclusion criteria and
type of infection. Secondly, this open, uncontrolled, retro-
spective study included a heterogeneous group of patients
with BJI. Thirdly, as late relapses may occur, especially when
an implant is infected, a follow-up period of > 1 year would
have provided additional data on the outcome of our
patients.
The results of the present retrospective study suggest that
both RLC and RCC prolonged oral therapy are equally effec-
tive in treating patients with BJI caused by GPC, including
infected orthopaedic devices. However, the lower daily cost
of cotrimoxazole (US$1) vs. linezolid (> US$100) renders
RCC an attractive alternative to RLC. Further wide-scale
clinical studies are warranted to conﬁrm these preliminary
results.
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